

Reference:	FOI.17803.25
Subject:	Myeloma
Date of Request:	14 July 2025

Requested:

1. Is your health board currently treating myeloma patients
2. Please list the hospitals in your board that are currently treating myeloma patients.
3. Please list how many myeloma patients are being treated by your board. Please break this down by hospital.
4. Is your health board currently treating myeloma patients with elranatamab or teclistamab. Please break this down by hospital.
5. Please list how many people have been given a) elranatamab or b) teclistamab since approval by the National Institute of Health and Care Excellence in 2024 (TA1023 and TA1015). If possible, please break this down by hospital.
6. Do you have a service level agreement or referral system in place with any other health boards to deliver
 - a. elranatamab or
 - b. teclistamab to patients. If the answer to this question is yes, which health boards do you have an agreement in place with.

Response:

Hywel Dda University Health Board (UHB) is unable to provide you with some of the information requested for question 3, as it is estimated that the cost of answering your request would exceed the “appropriate limit” as stated in the Freedom of Information Act 2000 (Appropriate Limit and Fees) Regulations 2004. The “appropriate limit” represents the estimated cost of one person spending 18 hours (or 2½ working days) in determining whether the UHB holds the information, and locating, retrieving and extracting the information.

In order to provide you with all of the information requested for the number of Myeloma patients that are receiving active treatments, the UHB would need to undertake a manual trawl to identify all the information that would fulfil your request. Cancer treatments for Myeloma patients can be undertaken within a hospital or via homecare and therefore, the UHB would need to identify all Myeloma patients, exclude those receiving treatment in hospital, recorded on ChemoCare. Before cross referencing those left on the list with each Cancer Consultant, to identify if a patient is receiving treatment via homecare as this is not recorded centrally.

Under its Section 16 duty to provide advice and assistance, the UHB has identified one hundred and fifty-one (151) Myeloma patients who are receiving active cancer treatments within the hospital setting. Therefore, if the UHB were to assume that the same amount of myeloma patients were receiving treatment at home, this would far exceed the ‘appropriate limit’, costing the UHB the following:

151 @ 15 minutes per item = 37.75 hours
 37.75 hours @ £25 per hour = £943.75

The UHB is therefore applying an exemption under Section 12 of the Freedom of Information Act 2000 (FoIA), which provides an exemption from a public authority's obligation to comply with a request for information where the cost of compliance is estimated to exceed the appropriate limit.

However, under Section 16 of the FoIA, the UHB is required as a public authority, to provide advice and assistance so far as it is reasonable to individuals who have made a request under the FoIA, this can include assisting a requestor to further refine their request.

Unfortunately, the UHB is unable to provide advice on how you can refine your request further. This is due to the UHB still requiring a manual trawl of Myeloma patient records to be undertaken to identify any information requested around those patients receiving homecare treatments.

1. The UHB can confirm it does treat Myeloma patients.
2. The UHB confirms it treats Myeloma patients at the following hospitals:
 - Bronglais General Hospital (BGH)
 - Withybush General Hospital (WGH)
 - Glangwili General Hospital (GGH)
 - Prince Philip Hospital (PPH)
3. Section 12 exemption applied to homecare treatments. However, the UHB provides within the table below, the number of Myeloma patients that are receiving active treatments as recorded on the ChemoCare system, split by hospital site, as of 7 August 2025.

Hospital Site	Number
Bronglais General Hospital (BGH)	30
Glangwili General Hospital (GGH)	41
Prince Philip Hospital (PPH)	35
Withybush General Hospital (WGH)	45

In addition to this the UHB has 450 patients recorded on the ChemoCare system as being in receipt of maintenance treatments.

4. The UHB confirms it is not currently treating Myeloma patients with Elranatamab or Teclistamab.
5. The UHB provides within the table below, the number of patients who have been treated with the listed medications for any condition, since approval by the National Institute of Health and Care Excellence in 2024, split by hospital site.

Treatment	Number	Hospital Site
Elranatamab	*	GGH
Teclistamab	0	Not applicable

Where the figures in the table above have been replaced with an asterisk (*), the UHB is unable to provide you with the exact number of patients due to the low number of cases (less than 5), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000 (FoIA). This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations, as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles

and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

6a. The UHB confirms it has an informal agreement with Swansea Bay University Health Board (SBUHB) to refer patients for Elranatamab.

6b. The UHB confirms it has an informal agreement with Swansea Bay University Health Board (SBUHB) to refer patients for Teclistamab.